117 related articles for article (PubMed ID: 36632663)
1. Erratum to Discovery of a Novel Potent Antitumor Molecule, P19G1, by Erlotinib Derivative.
Technol Cancer Res Treat; 2023; 22():15330338221149552. PubMed ID: 36632663
[No Abstract] [Full Text] [Related]
2. Discovery of a Novel Potent Antitumor Molecule, P19G1, by Erlotinib Derivative Libraries Synthesized by Modular Click-Chemistry.
Cui Q; Song P; Ma T; Wang Z; Lu X; Shi Y; Zhang F; Lin G; Dong J; Zhang J
Technol Cancer Res Treat; 2022; 21():15330338221109649. PubMed ID: 36303409
[No Abstract] [Full Text] [Related]
3. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
Chen J; Smith M; Kolinsky K; Adames V; Mehta N; Fritzky L; Rashed M; Wheeldon E; Linn M; Higgins B
Cancer Chemother Pharmacol; 2007 Apr; 59(5):651-9. PubMed ID: 16937104
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole.
Deng P; Sun G; Zhao J; Yao K; Yuan M; Peng L; Mao L
Front Pharmacol; 2021; 12():793905. PubMed ID: 35111061
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
Gallagher-Colombo SM; Miller J; Cengel KA; Putt ME; Vinogradov SA; Busch TM
Cancer Res; 2015 Aug; 75(15):3118-26. PubMed ID: 26054596
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Evaluation of Novel Carbohydrate-Derived Derivatives of Erlotinib.
Yu W; Jiang L; Shen C; Zhang P
Drug Dev Res; 2016 Sep; 77(6):319-25. PubMed ID: 27521056
[TBL] [Abstract][Full Text] [Related]
9. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
12. Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice.
Lin P; An F; Xu X; Zhao L; Liu L; Liu N; Wang P; Liu J; Wang L; Li M
Biochem Biophys Res Commun; 2015 May; 460(2):362-7. PubMed ID: 25791480
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Tsai AC; Pai HC; Wang CY; Liou JP; Teng CM; Wang JC; Pan SL
Br J Pharmacol; 2014 Jan; 171(1):122-33. PubMed ID: 24116948
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib: preclinical investigations.
Hidalgo M
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):11-6. PubMed ID: 14682118
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
Ling YH; Li T; Yuan Z; Haigentz M; Weber TK; Perez-Soler R
Mol Pharmacol; 2007 Aug; 72(2):248-58. PubMed ID: 17456787
[TBL] [Abstract][Full Text] [Related]
17. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
18. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Friess T; Scheuer W; Hasmann M
Clin Cancer Res; 2005 Jul; 11(14):5300-9. PubMed ID: 16033849
[TBL] [Abstract][Full Text] [Related]
20. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Wilson C; Nicholes K; Bustos D; Lin E; Song Q; Stephan JP; Kirkpatrick DS; Settleman J
Oncotarget; 2014 Sep; 5(17):7328-41. PubMed ID: 25193862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
